QLT at neutral by Merrill on jury decision

Merrill Lynch analyst Hari Sambasivam rated QLT, Inc. at neutral after a jury ruled that the company was liable for "unjust enrichment and unfair trade practices" related to a patent that was co-owned by QLT, the Massachusetts Eye & Ear Infirmary (MEEI) and the Massachusetts General Hospital covering the use of verteporfin (Visudyne) in eye diseases. As a result, QLT is required to pay the MEEI 3.01% of net worldwide Visudyne sales. Shares of the Vancouver, B.C.-based biopharmaceutical company were down 17 cents, or 2.01%, at $8.28. (Nasdaq: QLTI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.